18. Decreased circulatory volume Activation of central baroreceptors Norepinephrine Vasopressin Angiotensin II PGE2 / PGI2 Nitric oxide Autoregulation (MAP > 70) Vasoconstriction Mesangial contraction Reduced renal blood flow & GFR Prerenal
19.
20. Functional & Physiologic change Loss of cell polarity Loss Cell-cell, cell matrix interaction Tight junction defect ↑ Distal Na delivery Tubular obstruction Back leak Renal vasoconstriction ↓ GFR Tubuloglomerular feedback Brush border detachment
21.
22. Na + K + Cl - Medullary ischemia Intermediate syndrome Urine Na low Urine spgr low
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35. RENAL Na + REABSORPTION HCO 3 - HCO 3 - + H 2 O+CO 2 CA H + +HCO 3 - CA Na + glucose PO 4 AA Carbonic anhydrase inhibitor H + Na + 3 HCO 3 - Na + 3Na + 2K + 3Na + 2K + 3HCO 3 - Na +
61. hypotonic isotonic colloid ICF 2/3 ECF 1/3 II 3/4 IV 1/4 TBW - male : 60%BW, Female 50%BW Elder - male : 50%BW, Female 45%BW Children : 60%BW
62.
63. Bunn F, Trivedi D, Ashraf S. Colloid solutions for fluid resuscitation. Cochrane Database of Systematic Reviews 2008, Issue 1. Art. No.: CD001319. DOI: 10.1002/14651858.CD001319.pub2. There is no evidence that one colloid solution is more effective or safe than any others (albumin, PPF, dextran, HES, gelatin) There is no evidence from RCTs that resuscitation with colloids reduces the risk of death, compared to resuscitation with crystalloids,in patients with trauma, burns or following surgery. Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD000567. DOI: 10.1002/14651858.CD000567.pub3.
100. TREATMENT mechanism onset peak Ca antagonist 1-5 min HD remove 15 min PD remove 2 h Kay exalate remove 1-6 h NaHCO 3 shift unreliable Insulin shift 1 0 - 2 0 min 1-2 h B2 agonist shift 1 0 - 20 min 1-2 h
128. Approach to Patients with Glomerular Diseases Suchai Sritippayawan Division of Nephrology , Internal Medicine, Siriraj Hospital, Mahidol University